Lonza Pharma & Biotech and Innosieve Diagnostics announced today an exclusive distribution agreement for rapid bioburden testing technology. This agreement expands Lonza’s extensive offering of ...

The bioburden testing market presents opportunities driven by stringent regulations and the need for contamination control in ...

Another driver contributing to the market growth is the growing emphasis on regulatory compliance. Regulatory authorities across the globe are imposing strict guidelines and regulations regarding ...

The quality of water for pharmaceutical production (purified water, water for injection, and ultrapure water) is quantified and regulated through four parameters – total organic carbon (TOC), ...

When sterilizing medical devices, sterilization personnel rely on bioburden counts as part of determining and maintaining the sterilization process. In the following Q&A, Martell Winters, senior ...

The bioburden testing market is projected to experience significant growth due to the increasing demand for quality assurance and safety measures in various industries. The rising awareness about the ...

North America dominated the bioburden testing market with the largest share of 36.42% in 2025. The Asia Pacific is expected to be the fastest-growing region in the bioburden testing market during the ...

Researchers and therapeutic manufacturers have long relied on classical microbiological methods to check their samples and surfaces for microbial contamination, primarily using lengthy ...